Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (SHE:300534)
China · Delayed Price · Currency is CNY 8.44
-0.25 (-2.88%)
May 21, 2026, 3:04 PM CST
SHE:300534 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 822.17 | 865.26 | 1,028 | 1,067 | 788.26 | 280.05 |
Other Revenue | 21.7 | 21.7 | 14.88 | 12.89 | 11.42 | 7.77 |
| 843.87 | 886.96 | 1,043 | 1,080 | 799.68 | 287.81 | |
Revenue Growth (YoY) | -20.56% | -14.92% | -3.48% | 35.06% | 177.85% | 12.91% |
Cost of Revenue | 280.64 | 283.41 | 291.37 | 386.79 | 341.62 | 195.48 |
Gross Profit | 563.23 | 603.55 | 751.13 | 693.26 | 458.06 | 92.33 |
Selling, General & Admin | 433.66 | 467.9 | 617.94 | 560.01 | 364.37 | 90.06 |
Research & Development | 27.15 | 27.15 | 28.13 | 30.17 | 27.12 | 6.7 |
Other Operating Expenses | 13.96 | 13.56 | 13.22 | 12.34 | 4.99 | 3.75 |
Operating Expenses | 482.23 | 516.08 | 655.12 | 611.43 | 401.75 | 101.65 |
Operating Income | 81 | 87.47 | 96.02 | 81.82 | 56.31 | -9.31 |
Interest Expense | -2.66 | -2.66 | -3.34 | -3.95 | -0.5 | -0.53 |
Interest & Investment Income | 4.74 | 4.74 | 7.39 | 7.17 | 4.3 | 2.32 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0 | 0.01 | 0.02 | -0.06 |
Other Non Operating Income (Expenses) | 15 | 0.11 | -2.06 | 0 | 2.1 | -0.11 |
EBT Excluding Unusual Items | 98.07 | 89.66 | 98 | 85.05 | 62.24 | -7.7 |
Impairment of Goodwill | - | - | - | - | - | -4.78 |
Gain (Loss) on Sale of Investments | -0 | -0 | -0.21 | - | - | - |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | -0.69 | -0.24 | - | 0.06 |
Asset Writedown | - | - | - | - | -0.1 | - |
Other Unusual Items | -8.5 | -8.5 | 4.66 | 12.2 | 4 | 7.67 |
Pretax Income | 89.56 | 81.15 | 101.76 | 97.02 | 66.14 | -4.75 |
Income Tax Expense | 17.09 | 15.78 | 51.68 | 13.17 | 17.49 | 1.55 |
Earnings From Continuing Operations | 72.47 | 65.36 | 50.08 | 83.85 | 48.65 | -6.3 |
Minority Interest in Earnings | -23.1 | -21.41 | -25.6 | -22.2 | -9.87 | -2.81 |
Net Income | 49.37 | 43.95 | 24.48 | 61.65 | 38.79 | -9.11 |
Net Income to Common | 49.37 | 43.95 | 24.48 | 61.65 | 38.79 | -9.11 |
Net Income Growth | 129.18% | 79.56% | -60.30% | 58.95% | - | - |
Shares Outstanding (Basic) | 303 | 303 | 303 | 303 | 303 | 304 |
Shares Outstanding (Diluted) | 303 | 303 | 303 | 303 | 303 | 304 |
Shares Change (YoY) | 0.02% | 0.01% | -0.03% | 0.05% | -0.10% | -0.54% |
EPS (Basic) | 0.16 | 0.14 | 0.08 | 0.20 | 0.13 | -0.03 |
EPS (Diluted) | 0.16 | 0.14 | 0.08 | 0.20 | 0.13 | -0.03 |
EPS Growth | 129.14% | 79.55% | -60.28% | 58.87% | - | - |
Free Cash Flow | -14.76 | -49.9 | 137.23 | -29.83 | 242.03 | 50.72 |
Free Cash Flow Per Share | -0.05 | -0.17 | 0.45 | -0.10 | 0.80 | 0.17 |
Dividend Per Share | 0.040 | 0.040 | 0.040 | 0.020 | - | - |
Dividend Growth | - | - | 100.00% | - | - | - |
Gross Margin | 66.74% | 68.05% | 72.05% | 64.19% | 57.28% | 32.08% |
Operating Margin | 9.60% | 9.86% | 9.21% | 7.58% | 7.04% | -3.24% |
Profit Margin | 5.85% | 4.96% | 2.35% | 5.71% | 4.85% | -3.16% |
Free Cash Flow Margin | -1.75% | -5.63% | 13.16% | -2.76% | 30.27% | 17.62% |
EBITDA | 123.52 | 129.18 | 134.51 | 111.73 | 83.3 | 13.25 |
EBITDA Margin | 14.64% | 14.56% | 12.90% | 10.34% | 10.42% | 4.60% |
D&A For EBITDA | 42.51 | 41.71 | 38.5 | 29.9 | 26.99 | 22.56 |
EBIT | 81 | 87.47 | 96.02 | 81.82 | 56.31 | -9.31 |
EBIT Margin | 9.60% | 9.86% | 9.21% | 7.58% | 7.04% | -3.24% |
Effective Tax Rate | 19.09% | 19.45% | 50.78% | 13.57% | 26.44% | - |
Revenue as Reported | 886.96 | 886.96 | 1,043 | 1,080 | 799.68 | 287.81 |
Advertising Expenses | - | 0.69 | 0.95 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.